AH
Anders Hove Portfolio
Invests via Acorn Capital Advisors LLC | Managed by Anders Hove
Invests via Acorn Capital Advisors LLC
Managed by Anders Hove
Automatically Tracked
Seasoned Scandinavian entrepreneur and investor with operational experience in scaling technology and healthcare businesses. Anders Hove is known for leading growth-stage companies, directing strategic M&A, and allocating capital across early-stage venture and private equity. Focus areas include enterprise software, healthtech and real assets; typical involvement spans board roles, active portfolio management and follow-on financing. Market-minded profile useful for LP introductions, deal sourcing and strategic partnerships.
Seasoned Scandinavian entrepreneur and investor with operational experience in scaling technology and healthcare businesses. Anders Hove is known for leading growth-stage companies, directing strategic M&A, and allocating capital across early-stage venture and private equity. Focus areas include enterprise software, healthtech and real assets; typical involvement spans board roles, active portfolio management and follow-on financing. Market-minded profile useful for LP introductions, deal sourcing and strategic partnerships.
Investment Philosophy & Strategy
Seasoned operator-investor who favors growth-stage, value-creating opportunities at the intersection of enterprise software, healthtech and real assets. Deploys capital with a hands-on, board-active approach, prioritizing companies with repeatable unit economics, clear M&A optionality and measurable path to profitability. Time horizon is medium-to-long; risk discipline combines staged financings, follow-on reserves and strategic partnerships to accelerate exits and protect downside.
Seasoned operator-investor who favors growth-stage, value-creating opportunities at the intersection of enterprise software, healthtech and real assets. Deploys capital with a hands-on, board-active approach, prioritizing companies with repeatable unit economics, clear M&A optionality and measurable path to profitability. Time horizon is medium-to-long; risk discipline combines staged financings, follow-on reserves and strategic partnerships to accelerate exits and protect downside.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
166.15%
Gain +6.97%
Monthly
5.16%
Yearly
83.04%
Drawdown
29.37%
$396.34M
Equity
Holdings
$396.34M
Investment
$202.34M
$259.31M
Profit +$20.76M
Realized
$65.32M
Unrealized
$194M
Dividends
$11.4
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
6.97%
Profit
$20.76M
Win %
71%
This Week
Compared To Last Week
Gain
5.81%
Profit
$21.77M
Win %
71%
This Month
Compared to last month
Gain
13.46%
Profit
$47.01M
Win %
71%
This Year
Compared to last year
Gain
9.27%
Profit
$33.61M
Win %
63%
HELP Cybin Inc.
+4.72%
+$831,743.64 
JBIO Jade Biosciences Inc.
+3.78%
+$888,084 
BCAX Bicara Therapeutics Inc.
+2.75%
+$418,197.65 
OKUR OnKure Therapeutics Inc.
+2.31%
+$255,570.66 
TRVI Trevi Therapeutics Inc.
+1.71%
+$664,901.64 
KPTI Karyopharm Therapeutics Inc.
+1.51%
+$45,543.39 
PBYI Puma Biotechnology Inc.
+1.38%
+$495,755.88 
LONA Athira Pharma Inc.
+1.21%
+$60,281.21 
TARA Protara Therapeutics Inc.
+0.76%
+$52,563.45 
ENGN enGene Therapeutics Inc.
+0.59%
+$12,712.57 
AURA Aura Biosciences Inc.
+0.52%
+$37,163.08 
CGON CG Oncology, Inc.
+0.43%
+$362,078.87 
URGN Urogen Pharma Ltd.
+0.21%
+$167,342 
BCAB BioAtla, Inc.
-10.44%
-$38,925.36 
JSPR Jasper Therapeutics Inc.
-8.46%
-$104,985.55 
WHWK Whitehawk Therapeutics, Inc.
-4.7%
-$250,659.86 
QTTB Q32 Bio Inc.
-1.43%
-$47,557.62 
VSTM Verastem Inc.
-1.35%
-$132,223.77 
CADL Candel Therapeutics Inc.
-0.68%
-$279,835.84 
VYNE Vyne Therapeutics Inc.
-0.54%
-$6.55 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 79 | Longs Won 42/79 53% | Profit Factor 6.63 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $12.71M |
| Average Win $7.27M | Best Trade (Jun 29) $82.39M | Sharpe Ratio -8.7 |
| Average Loss -$1.25M | Worst Trade (Sep 29) -$9.5M | Z-Score 1.86 (93.64%) |
| Commissions $0 | Avg. Trade Length 11m 2w | Expectancy $3.28M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.03% | 0.35% | 2.92% | 18.84% |
| Consecutive Losing Trades | 318 | 286 | 255 | 223 | 191 | 159 | 127 | 95 | 64 | 32 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences Inc. | 929,077 | $5.86M | $7.14M | - | $1.28M | 21.93% | +0.523% |
| BCAB BioAtla, Inc. | 108,126 | $2.79M | $334,109.34 | - | -$2.46M | -88.04% | -10.435% |
| BCAX Bicara Therapeutics Inc. | 643,381 | $11.21M | $15.62M | - | $4.41M | 39.38% | +2.751% |
| CADL Candel Therapeutics Inc. | 3.5M | $24.72M | $41M | - | $16.28M | 65.85% | -0.678% |
| CGON CG Oncology, Inc. | 1.13M | $32.49M | $84.9M | - | $52.4M | 161.27% | +0.428% |
| ENGN enGene Therapeutics Inc. | 1.27M | $2.2M | $2.16M | - | -$38,138.09 | -1.73% | +0.592% |
| HELP Cybin Inc. | 1.54M | $13.05M | $18.47M | - | $5.42M | 41.49% | +4.716% |
| JBIO Jade Biosciences Inc. | 986,760 | $15.5M | $24.38M | - | $8.88M | 57.33% | +3.78% |
| JSPR Jasper Therapeutics Inc. | 1.44M | $3.15M | $1.14M | - | -$2.01M | -63.91% | -8.459% |
| KPTI Karyopharm Therapeutics Inc. | 1.52M | $12.68M | $3.07M | - | -$9.61M | -75.81% | +1.508% |
| LONA Athira Pharma Inc. | 634,539 | $5.16M | $5.05M | - | -$109,244.86 | -2.12% | +1.207% |
| OKUR OnKure Therapeutics Inc. | 2.84M | $8.02M | $11.33M | - | $3.31M | 41.21% | +2.308% |
| PBYI Puma Biotechnology Inc. | 4.13M | $12.54M | $36.48M | - | $23.94M | 190.93% | +1.378% |
| QTTB Q32 Bio Inc. | 216,171 | $743,628.24 | $3.27M | - | $2.53M | 340.41% | -1.431% |
| TARA Protara Therapeutics Inc. | 1.75M | $8.19M | $6.96M | - | -$1.23M | -15.05% | +0.761% |
| TRVI Trevi Therapeutics Inc. | 2.14M | $9.15M | $39.59M | - | $30.45M | 332.78% | +1.708% |
| URGN Urogen Pharma Ltd. | 1.67M | $21.88M | $80.69M | - | $58.81M | 268.79% | +0.208% |
| VSTM Verastem Inc. | 1.47M | $9.41M | $9.67M | - | $258,006.89 | 2.74% | -1.349% |
| VYNE Vyne Therapeutics Inc. | 28.5 | $2,251.5 | $1,210.96 | - | -$1,040.54 | -46.22% | -0.538% |
| WHWK Whitehawk Therapeutics, Inc. | 1.14M | $3.59M | $5.08M | - | $1.49M | 41.36% | -4.701% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Anders Hove?
The largest contributions to the portfolio's profits come from the following stocks: Terns Pharmaceuticals, Inc - $90.23M, Q32 Bio Inc - $1.34M, OPTN - $1.05M, Urogen Pharma Ltd - $782,489.44, and CG Oncology, Inc - $39,059.84. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Y-mAbs Therapeutics Inc - $9.47M, OnKure Therapeutics Inc - $5.33M, X4 Pharmaceuticals Inc - $4.48M, Cardiff Oncology Inc - $4.12M, and Vyne Therapeutics Inc - $1.58M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Anders Hove's portfolio generate?
The portfolio generates substantial dividend income, with a total of $11.4 earned over time. The largest contributors to dividend income include Vyne Therapeutics Inc - $11.4. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Anders Hove's monthly returns?
Anders Hove's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Anders Hove's strategy be considered aggressive or moderate?
Anders Hove's strategy appears moderately aggressive. The portfolio shows a clear focus on growth, with noticeable volatility and risk exposure, although not to an extreme level. This type of strategy may appeal to users seeking higher returns while accepting meaningful fluctuations along the way.
Should beginners follow Anders Hove's strategy?
Anders Hove's strategy is probably not ideal for beginners. The combination of risk, volatility, or portfolio complexity may make it harder to follow and understand without prior experience. Users who are new to investing may find it challenging to replicate or tolerate the performance swings.
